November 2021 - Page 2 of 4 - BioMedWire (BMW)

MondayNov 22, 2021 8:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Updating Trial Protocols in Response to FDA Request as Tryp Prepares Synthetic Psilocybin Studies for Eating Disorder, Fibromyalgia Treatment

Pharmaceutical company Tryp Therapeutics is investigating the potential of synthetic psychedelic drug candidates to treat unmet medical needs The company is evaluating two drug products labeled TRP-8802 and TRP-8803 for treating fibromyalgia, phantom limb pain, complex regional pain syndrome and select eating disorders The company has filed its first two INDs with the FDA for planned Ph 2a clinical trials relating to fibromyalgia and eating disorder treatments In the wake of changes recommended by the FDA to the eating disorders trial, Tryp is in the process of updating its protocols and patient consent form to meet the FDA’s expectations Tryp…

FridayNov 19, 2021 9:30 am

Large Trial Finds Psilocybin Efficacious Against Depression

Compass Pathways recently released results from a phase 2b trial, which was focused on evaluating the effectiveness of psilocybin as a treatment for depression. The results, which were announced earlier last week, show that the psychedelic substance was highly effective as a treatment for treatment-resistant depression. For their study, the researchers recruited more than 200 sites in different locations in North America and Europe. This study was the largest double-blind randomized controlled trial on psilocybin, which is an active compound found in hallucinogenic mushrooms. The company stated that it observed a significant reduction in symptoms of depression in patients who…

FridayNov 19, 2021 8:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Moves ‘One Step Closer’ to Creating Best Therapy for Mental Health

Company releases positive results from preclinical study focusing on psilocybin program CYB003 Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental healthcare Results indicate less patient variability, faster onset of action, shorter duration of effect and improved brain penetration According to the National Institute of Mental Health, some 17.3 million Americans, or more than 7% of the country’s entire population, suffer from major depressive disorder (“MDD”) (https://ibn.fm/0GSuV). This demographic can look to Cybin (NEO: CYBN) (NYSE American: CYBN) for help; the pharmaceutical company has announced positive results from a preclinical study focusing on CYB003, one of…

ThursdayNov 18, 2021 9:49 am

Study Explores Link Between Obstructive Sleep Apnea and COVID-19

Obstructive sleep apnea ("OSA") is a common sleep-related breathing disorder that causes individuals to repeatedly start and stop breathing while they sleep. There exist different types of sleep apnea, with the most common one being obstructive sleep apnea. Common symptoms of this particular type of sleep apnea include loud snoring, excessive daytime sleepiness, episodes of stopped breathing and awakening abruptly, which may be accompanied by choking or gasping. A new study has found that patients with COVID-19 who suffer from obstructive sleep apnea have longer hospital stays and higher mortality rates when compared to patients with the coronavirus who don’t…

ThursdayNov 18, 2021 8:00 am

Nemaura Medical Inc. (NASDAQ: NMRD) Offers ‘First-of-a-Kind’ Device in Growing CGM Market

The global continuous glucose monitoring devices market size is expected to reach $19.04 billion in 2028 The increasing prevalence of diabetes, rising focus on preventive care are significant factors in the steady revenue growth Nemaura Medical’s sugarBEAT device allows individuals to make adjustments to diet and activity that can significantly change their lives According to a recent Reports and Data release, the global consumer monitoring (“CGM”) devices global market is forecast to see notable growth in the coming years (https://ibn.fm/LhWNO). Key companies operating in the space, including Nemaura Medical (NASDAQ: NMRD), are ideally positioned to benefit from that growth as they work…

WednesdayNov 17, 2021 1:22 pm

Mental Health Conditions, IBS Could Have Shared Origins

Irritable bowel syndrome (“IBS”) is a condition that affects one in every ten individuals globally. Its symptoms include bowel dysfunction and bloating and abdominal pain among others, which can significantly impact an individual’s life. Before a diagnosis can be made, clinicians usually consider the possibility of other ailments, including bowel cancer and Crohn’s disease. IBS is common in individuals who are prone to anxiety. While its causes aren’t well understood, a group of researchers recently discovered some genes that offer leads into its origin. The group was made up of more than 40 institutions, with the research being coordinated by…

TuesdayNov 16, 2021 9:30 am

Insufficient Sleep Compromising Students’ Mental Well-Being

A new study has found that more than one-half of students experience poor sleep quality, with researchers noting that lack so sleep has been associated to mental health issues. The study was published in the “Annals of Human Biology” journal. It is part of the longitudinal study on the lifestyle and health of students in universities. The study involved 1,113 women and men who attend university on a full-time basis, all aged between 16 and 25. Each participant was asked about their socioeconomic status and sleep quality, with researchers also assessing their body mass index. The researchers used this data…

MondayNov 15, 2021 9:30 am

Veterans Urged to Undergo Lung Cancer Screening During Lung Cancer Awareness Month

Cancer begins when old cells in an individual’s body begin to mutate instead of dying, growing out of control and creating abnormal cells. A team of oncologists, cardiothoracic surgeons and specialized nurse navigators from the Central Virginia Care System are urging veterans as well as individuals in high-risk groups to get screened for lung cancer this November, which is designated as Lung Cancer Awareness Month. Lung cancer is a type of cancer that starts in the lungs and is among the leading causes of cancer deaths around the globe. The primary types of lung cancer are non-small cell lung cancer…

MondayNov 15, 2021 8:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Files Technology Patent Application Covering Bioavailability-Enhancing, Nanoemulsion-Empowered Formulations

Mydecine has filed a technology patent application that allows for the creation of nanoemulsion-empowered formulations to improve, stabilize, and increase the bioavailability of ingredients The company aims to use the nanoemulsion technology to enhance the bioavailability and optimize the delivery of compounds that are inspired by traditional ingredients In September, Mydecine filed its final patent application for MYCO-003, one of its lead drug candidates for enhanced treatment of anxiety and post-traumatic stress disorder MYCOF is steadily strengthening its IP portfolio as it seeks to reimagine the treatment of mental health and addiction Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF), an…

FridayNov 12, 2021 12:19 pm

Recent Sector News Reveals Positive Data in Psychedelic Treatments For Depression as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Nears Launch of Synthetic Psilocybin Trials

Pharmaceutical company Tryp Therapeutics is developing a proprietary synthetic hallucinogen as potential medical solutions for select unmet health needs, with a focus on taking psychedelic therapeutics beyond mental health The company recently attended the Wonderland: Miami where Compass Pathways unveiled highly anticipated data from their Phase 2b trial in treatment-resistant depression Tryp’s Chairman and CEO Greg McKee served on a panel at Wonderland: Miami discussing the potential of synthetic psilocybin in chronic pain indications and the importance of supporting industry wins Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) Chairman and CEO Greg McKee recently participated in Microdose’s Wonderland: Miami conference as…

News and publishing service for medical and biotechnology related companies

Contact us: 415.949.5050

Month: November 2021

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Updating Trial Protocols in Response to FDA Request as Tryp Prepares Synthetic Psilocybin Studies for Eating Disorder, Fibromyalgia Treatment

Large Trial Finds Psilocybin Efficacious Against Depression

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Moves ‘One Step Closer’ to Creating Best Therapy for Mental Health

Study Explores Link Between Obstructive Sleep Apnea and COVID-19

Nemaura Medical Inc. (NASDAQ: NMRD) Offers ‘First-of-a-Kind’ Device in Growing CGM Market

Mental Health Conditions, IBS Could Have Shared Origins

Insufficient Sleep Compromising Students’ Mental Well-Being

Veterans Urged to Undergo Lung Cancer Screening During Lung Cancer Awareness Month

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Files Technology Patent Application Covering Bioavailability-Enhancing, Nanoemulsion-Empowered Formulations

Recent Sector News Reveals Positive Data in Psychedelic Treatments For Depression as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Nears Launch of Synthetic Psilocybin Trials

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search